PRDX1 and breast neoplasm: As a major consumer of intracellular NAD+, SIRT2 inhibits the peroxidase activity of Peroxiredoxin-1 (Prdx-1) through deacetylation, sensitizing breast tumor cells to increased reactive oxygen species (ROS) levels (Fiskus et al., 2016).